This syndrome shares numerous clinical features (such CVST and hemorrhagic transformation) and biological findings (including sometimes profound thrombocytopenia and the presence of anti-PF4 antibodies with heparin-independent platelet activation properties) with VITT, but occurs in the absence of prior heparin exposure or recent adenoviral vector vaccination [36]. This evidence concerns the gene PF4 and Thrombocytopenia.